GSK (LON:GSK) Stock Rating Upgraded by Deutsche Bank Aktiengesellschaft

GSK (LON:GSK – Get Rating) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft to a “buy” rating in a research report issued to clients and investors on Friday, March 17th, MarketBeat Ratings reports.

Other research analysts also recently issued research reports about the company. Credit Suisse Group reissued a “neutral” rating and set a GBX 1,510 ($18.54) target price on shares of GSK in a research note on Thursday, February 2nd. Shore Capital reiterated a “buy” rating on shares of GSK in a report on Friday, February 24th. The Goldman Sachs Group set a GBX 2,000 ($24.56) price objective on GSK in a research note on Monday, March 6th. JPMorgan Chase & Co. set a GBX 1,400 ($17.19) price objective on GSK in a report on Thursday, March 2nd. Finally, Jefferies Financial Group set a GBX 1,575 ($19.34) target price on GSK in a research note on Wednesday, February 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of GBX 1,573.33 ($19.32).

GSK Stock Performance

Shares of GSK opened at GBX 1,421.40 ($17.46) on Friday. The company has a debt-to-equity ratio of 207.87, a quick ratio of 0.73 and a current ratio of 0.91. GSK has a twelve month low of GBX 1,280.92 ($15.73) and a twelve month high of GBX 2,280.50 ($28.01). The firm has a market cap of £58.14 billion, a P/E ratio of 1,262.34, a PEG ratio of 1.08 and a beta of 0.27. The firm’s 50 day moving average price is GBX 1,434.11 and its two-hundred day moving average price is GBX 1,406.09.

Insider Transactions at GSK

In other news, insider Emma Walmsley sold 28,576 shares of the business’s stock in a transaction dated Tuesday, February 14th. The stock was sold at an average price of GBX 1,487 ($18.26), for a total value of £424,925.12 ($521,828.71). In other GSK news, insider Emma Walmsley sold 28,576 shares of the firm’s stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of GBX 1,487 ($18.26), for a total value of £424,925.12 ($521,828.71). Also, insider Jonathan Symonds purchased 2,100 shares of the stock in a transaction dated Monday, March 20th. The shares were acquired at an average price of GBX 1,399 ($17.18) per share, with a total value of £29,379 ($36,078.84). Insiders acquired 2,117 shares of company stock valued at $2,962,765 in the last quarter. 0.72% of the stock is currently owned by corporate insiders.

About GSK

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.